• Increase
  • Decrease
  • Normal

Current Size: 100%

Educational Forum Videos

2017»

Link to 2017 IWMF Educational Forum Agenda

The ABCs of WM
Jeffrey Matous, MD – Colorado Blood Cancer Institute
Prepares the newly diagnosed to get the most out of the other videos and provides a refresher course for veteran WM’ers
The Patient Perspective on Being Newly Diagnosed
Peter DeNardis – IWMF Trustee
Provides the patient’s perspective about living with cancer upon diagnosis of WM

Link to Matous Powerpoint slides

Link to DeNardis Powerpoint slides

The Map of Current Treatment Options for WM
Craig Reeder, MD – Mayo Clinic Arizona
Reviews indications for therapy, differences in drug classes, side effects of therapy, treatment options for newly diagnosed and relapsed/refractory patient and discussed the role of stem cell transplantation
The Genetic Drivers of WM
Zachary Hunter, PhD – Dana-Farber Cancer Institute
Reviews the genetics, epigenetics, genomics of WM (MYD88 L265P and CXCR4 mutations), and the genomic response to treatment options

Link to Reeder Powerpoint slides

Link to Hunter Powerpoint slides

Meet a Young Investigator
Jonas Paludo, MD – Mayo Clinic Rochester
Reviews the clinical presentation and outcomes of young patients with WM
WELCOME DINNER
Meghan Gutierrez Lymphoma Research Foundation

Link to Paludo Powerpoint slides

No Powerpoint slides available

Immunotherapy – The Newest Treatment Route
Madhav Dhodapkar, MD – Yale University
Reviews basic immunology, what makes cancer immunotherapy special, what are the some of the current approaches and existing challenges/emerging approaches
New Insights into the Biology & Therapy of WM
Steven Treon, MD, PhD – Dana-Farber Cancer Institute
Reviews manifestations of WM, side effects, genomics, treatment options, upfront treatment (newly diagnosed), and relapsed/refractory treatment approaches

Link to Dhodapkar Powerpoint slides

Link to Treon Powerpoint slides

Clinical Trial News: What New Treatments Are Coming Down the Road?
Edward Libby, MD, Seattle Cancer Care Alliance
Reviews current and soon to be open clinical trials for WM
The Patient Perspective on Clinical Trials
Ron Ternoway, SGL from Nova Scotia
Provides the patient’s perspective about living with cancer and entering clinical trials for WM

Link to Libby Powerpoint slides

Link to Ternoway Powerpoint slides

Self-Care During Your WM Journey
Toni Dubeau, RN, NP – Dana-Farber Cancer Institute
Learn how exercise, supplements, diet, and fatigue affect your outcome
Overview of the IWMF-LLS Strategic Research Roadmap – Our Track for the Future
Stephen Ansell, MD, PhD – Mayo Clinic Rochester
Covers what is unique about WM, as well as, genomics, epigenomics, MYD88 L265P and CXCR4 mutations, survival, and treatment options

Link to Dubeau Powerpoint slides

Link to Ansell Powerpoint slides

The Burning Questions About WM
Morie Gertz, MD, FACP – Mayo Clinic Rochester
Raises questions and answers about WM, such as, “Are my kids going to get this? How long will I live? What can I do to live longer?” just to name a few
2017 Ask the Doctors Panel (noted researchers and clinicians answer, and sometimes debate, questions from the audience) Moderated by Dr. Guy Sherwood, IWMF

Link to Gertz Powerpoint slides

No Powerpoint slides available

2016»

Link to 2016 IWMF Educational Forum Agenda

Basics of WM for the Newly Diagnosed/First Timers Session
Dr. Jeffrey Matous, MD, & Megan Andersen, NP-C - Colorado Blood Cancer Institute
Prepares the newly diagnosed to get the most out of the other videos and provides a refresher course for veteran WM’ers
IWMF Research Roadmap Overview & Bone Marrow Tumor Microenvironment
Dr. Stephen Ansell, MD, PhD - Mayo Clinic, Rochester
Covers what is unique about WM, as well as, genomics, epigenomics, MYD88 L265P and CXCR4 mutations, survival, and treatment options

Link to Matous Powerpoint slides

Link to Ansell Powerpoint slides

Frontline Treatment Options & Side Effects
Dr. Jorge Castillo, MD - Dana Farber Cancer Institute
Reviews the manifestations of WM disease, NCCN guidelines for initiation of treatment for WM, single agent treatments, combination therapies, maintenance, and new directions, including frontier clinical trials at Dana Farber Cancer Institute
Cellular Immunotherapy for Lymphoid Cancers
Dr. Edward Stadtmauer, MD - University of Pennsylvania
Covers the manifestations of WM, immunologic approaches to overcome self-tolerance in lymphoma, rationale for cellular immunotherapy in lymphoma, adoptive T-cell therapy, second generation of CAR for B-cell malignancies, overview of activated/engineered T-cell therapy, CD19-targeted CAR T-cells for B-cell malignancies, phase I trial for CLL, results with diffuse large B-cell lymphoma, follicular lymphoma and adverse events, pilot study of CART19 in multiple myeloma, CART-BCMA cells for multiple myeloma, and potential strategies to improve CART therapy in lymphoma

Link to Castillo Powerpoint slides

Link to Stadtmauer Powerpoint slides

Translating Genomic Advances into Novel Therapies for WM
Dr. Steven Treon, MD, PhD - Dana Farber Cancer Institute
Reviews WM-centric toxicities with commonly used therapies and discusses new directions in WM based on the MYD88 L265P somatic mutation in WM. MYD88 and CXCR4 mutations are the most common mutations present in WM patients, respectively, while other mutations exist in WM at lower frequencies and remain to be investigated. MYD88 triggers BTK, and the BTK inhibitor ibrutinib is highly active in patients with MYD88 mutations. Lower response activity is observed in patients with CXCR4 mutations. Ulocuplumab is a novel CXCR4 inhbitor that will be entering Phase I testing in WM patients. BCL2 is overexpressed in WM, the BCL-2 inhibitor venetoclax has entered a dedicated Phase I/II Study in WM. New therapeutics under development include HCK and Myddosome assembly inhibitors
WM: An Exciting, Upbeat Story
Dr. Morton Coleman, MD - Weill Cornell Medical College
A wonderful overview of WM. Dr. Coleman discusses the frequency of various lymphoma subtypes in adults, with emphasis on WM and cancer drug development. He reviews the signaling pathways in WM, drugs that inhibit WM cell survival and discusses the challenges of combining drugs and limiting side effects

Link to Treon Powerpoint slides

Link to Coleman Powerpoint slides

2016 Ask the Doctors Panel
Noted researchers and clinicians answer, and sometimes debate, questions from the audience
Ali Handal Keynote Performance

No Powerpoint slides available

No Powerpoint slides available

2015»

Link to 2015 IWMF Educational Forum Agenda

I’ve Been Diagnosed With WM – What Now?
Dr. Joseph Mikhael - Mayo Clinic, Arizona
Reviews the basics of Waldenstrom’s Macroglobulinemia and how it is distinguished from myeloma and lymphoma. Discusses the importance of an accurate diagnosis in WM. Highlights the critical features to establishing the need to treat WM. Outlines the overall approach to therapy of WM. Empowers you for the rest of this conference and your disease “career"
I Need Treatment – First Line Treatments and Side-Effects
Dr. Larry Anderson, University of Texas Southwestern Medical Center
Covers diagnosis of WM (aka LPL) and treatment options

Link to Mikhael Powerpoint slides

Link to Anderson Powerpoint slides

My WM is Back – Relapsed/Refractory Treatments
Dr. Sheeba Thomas, MD Anderson Cancer Center
Explores diagnosis, recommendations for treating relapsed WM, clinical trials, and future therapies
The Garden Talk
Dr. Morie Gertz, Mayo Clinic, Rochester
An informative analogy of the person as a garden and the weeds as cancer cells and suggestions to prevent growth of cancer cells

Link to Thomas Powerpoint slides

No Powerpoint slides available

How B-Cells Work and Talk to Each Other
Dr. Stephen Ansell, Mayo Clinic, Rochester
Reviews how lymphocytes become plasma cells and then produce antibodies and activate the B-cell receptor pathway, the Toll-like receptor pathway, what caused the increased production of IgM in WM, cytokines, chemokines, receptor/ligand interactions and cell communications
Genomic Based Treatment Advances in WM
Dr. Steven Treon, Dana-Farber Cancer Institute
Explains the WM-centric toxicities with commonly used therapies and new treatment directions in WM, including MYD88 L265P mutation and the MYD88 L265P signal pathway, Ibrutinib studies, and its effect on side effects and survival, WHIM-like CXCR4 C-tail mutations in WM, unmutated MYD88 disease in WM, Idelalisib, clinical trial of ABT-199 (BCL2 inhibitor) in relapsed/refractory WM, resistance to Ibrutinib, Ixazomib clinical trial

Link to Ansell Powerpoint slides

Link to Treon Powerpoint slides

Ask the Doctors Panel (noted researchers answer, and sometimes debate, questions from the audience)
moderated by Dr. Robert Kyle, Mayo Clinic

No Powerpoint slides available

 

2014»

Link to 2014 IWMF Educational Forum Agenda

Progress in Indolent Lymphoma – Is Chemotherapy Dead? (Keynote speech)
Dr. Bruce Cheson, Georgetown University

Link to Cheson Powerpoint slides

Advances in the Management of WM Revealed by the Whole Genome
Dr. Steven Treon, Dana-Farber Cancer Institute

Link to Treon Powerpoint slides

The Burning Questions About WM
Dr. Morie Gertz, Mayo Clinic

Link to Gertz Powerpoint slides

Hematology 101
Dr. Rachid Baz, Moffitt Cancer Center

Link to Baz Powerpoint slides

Managing the Side Effects of Treatment
Dr. Jeffrey Matous, Colorado Blood Cancer Institute

Link to Matous Powerpoint slides

Ask the Doctors Panel (noted researchers answer , and sometimes debate, questions from the audience)
moderated by Dr. Robert Kyle, Mayo Clinic

No Powerpoint slides available

Section: 
Google Adwords: 

Did you know?

Did you know the 23rd Educational Forum will be at the Westin O’Hare Hotel in Rosemont IL from May 18-20, 2018?